Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings
This article was originally published in The Pink Sheet Daily
Executive Summary
The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.